Published in PLoS One on October 19, 2011
CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. BMC Syst Biol (2015) 1.12
Simulating cancer growth with multiscale agent-based modeling. Semin Cancer Biol (2014) 1.09
Mathematical modeling of the immune system recognition to mammary carcinoma antigen. BMC Bioinformatics (2012) 1.02
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00
Agent-based modeling of the immune system: NetLogo, a promising framework. Biomed Res Int (2014) 0.94
Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinformatics (2013) 0.88
Modeling innate immune response to early Mycobacterium infection. Comput Math Methods Med (2012) 0.87
State-transition diagrams for biologists. PLoS One (2012) 0.87
Cancer vaccines: state of the art of the computational modeling approaches. Biomed Res Int (2012) 0.87
Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies. AAPS J (2013) 0.85
A mathematical model of immune-system-melanoma competition. Comput Math Methods Med (2012) 0.79
Immune system modeling and related pathologies. Comput Math Methods Med (2012) 0.77
A methodological approach for using high-level Petri Nets to model the immune system response. BMC Bioinformatics (2016) 0.75
Mathematical Models for Immunology: Current State of the Art and Future Research Directions. Bull Math Biol (2016) 0.75
Optimal vaccination schedule search using genetic algorithm over MPI technology. BMC Med Inform Decis Mak (2012) 0.75
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation (2008) 1.64
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci (2008) 1.42
Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res (2002) 1.36
Optimization of HAART with genetic algorithms and agent-based models of HIV infection. Bioinformatics (2007) 1.24
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res (2004) 1.22
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform (2009) 1.19
Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics (2010) 1.19
In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res (2010) 1.17
ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci (2010) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol (2001) 1.07
Vaccine protocols optimization: in silico experiences. Biotechnol Adv (2009) 1.04
Modeling lymphocyte homing and encounters in lymph nodes. BMC Bioinformatics (2009) 1.03
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00
Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res (2005) 0.99
Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res (2009) 0.99
Optimal vaccination schedules using simulated annealing. Bioinformatics (2008) 0.92
Modeling immune system control of atherogenesis. Bioinformatics (2008) 0.89
Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy (2009) 0.87
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY. Immunome Res (2010) 0.86
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization. Brief Bioinform (2009) 1.19
Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics (2010) 1.19
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res (2010) 1.17
ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci (2010) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator. BMC Bioinformatics (2006) 1.14
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Combining cellular automata and Lattice Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion and immune competition. J Immunol Methods (2011) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
Vaccine protocols optimization: in silico experiences. Biotechnol Adv (2009) 1.04
A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03
Mathematical modeling of the immune system recognition to mammary carcinoma antigen. BMC Bioinformatics (2012) 1.02
Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00
Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem (2008) 0.98
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther (2006) 0.98
Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97
Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 0.96
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res (2012) 0.94
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol (2007) 0.93
Optimal vaccination schedules using simulated annealing. Bioinformatics (2008) 0.92
Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer (2011) 0.92
Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92
Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther (2005) 0.91
Interleukin-15 in gene therapy of cancer. Curr Gene Ther (2013) 0.91
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer (2007) 0.90
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 0.89
Modeling immune system control of atherogenesis. Bioinformatics (2008) 0.89
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol (2011) 0.89
Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinformatics (2013) 0.88
CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol (2012) 0.88
Cancer vaccines: state of the art of the computational modeling approaches. Biomed Res Int (2012) 0.87
Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clin Cancer Res (2009) 0.87
Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy (2009) 0.87
Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol (2010) 0.86
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res (2003) 0.86
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY. Immunome Res (2010) 0.86
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85
Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. J Invest Dermatol (2013) 0.85
T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol (2013) 0.84
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer (2010) 0.83
CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J (2012) 0.83
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Cell tracking using multimodal imaging. Contrast Media Mol Imaging (2013) 0.83
Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One (2011) 0.82
Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J Hepatol (2009) 0.82
Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 0.82
Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol (2007) 0.81
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med (2012) 0.80
Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. Exp Hematol (2002) 0.80
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther (2007) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One (2011) 0.79
Better performance of CARs deprived of the PD-1 brake. Clin Cancer Res (2013) 0.79
Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunol Immunother (2010) 0.79
Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res (2012) 0.78
Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther (2005) 0.77
The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. Immunotherapy (2012) 0.77
Awareness and understanding of cancer immunotherapy in Europe. Hum Vaccin Immunother (2014) 0.77
Biologic therapy of liver tumors. Surg Clin North Am (2004) 0.76
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp Hematol (2002) 0.76
Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. Arch Immunol Ther Exp (Warsz) (2002) 0.75
High-density lipoproteins delivering interleukin-15. Oncoimmunology (2013) 0.75
Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain. J Transl Med (2014) 0.75
MAGE antigens: therapeutic targets in hepatocellular carcinoma? J Hepatol (2004) 0.75
Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. Oncoimmunology (2012) 0.75
International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010. Cancer Immunol Immunother (2011) 0.75
Immunology and gene therapy: shoulder to shoulder into the fray. Mol Ther (2010) 0.75